Skip to main content

Vestibular Schwannoma

5
Pipeline Programs
9
Companies
9
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
457%
Gene Therapy
343%
+ 5 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
EndostatinPhase 2Small Molecule1 trial
Active Trials
NCT02104323Completed20Est. Apr 2016
Betta Pharmaceuticals
Betta PharmaceuticalsChina - Hangzhou
1 program
1
IcotinibPhase 2Small Molecule1 trial
Active Trials
NCT02934256Completed10Est. Jul 2018
Prevail Therapeutics
2 programs
1
AAVAnc80-antiVEGF via Akouos Delivery DevicePhase 1/21 trial
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy1 trial
Active Trials
NCT07503613Enrolling By Invitation100Est. Apr 2040
NCT06517888Recruiting27Est. Aug 2029
Akouos
AkouosMA - Boston
2 programs
1
AAVAnc80-antiVEGF via Akouos Delivery DevicePhase 1/2
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
lapatinibPhase 1Small Molecule1 trial
Active Trials
NCT00863122Completed26Est. Aug 2014
Advanced Bionics
Advanced BionicsCA - Valencia
2 programs
Cochlear ImplantN/A4 trials
Cochlear Implant for Vestibular Schwannoma or Meniere DiseaseN/A
Active Trials
NCT07035873Recruiting15Est. Mar 2027
NCT06301568Completed55Est. Dec 2024
NCT05488535Completed101Est. Feb 2020
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy
AAVAnc80-antiVEGF via Akouos Delivery DevicePHASE_1_2
GSK
GSKLONDON, United Kingdom
1 program
lapatinibPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Betta PharmaceuticalsIcotinib
BiocorpEndostatin
Prevail TherapeuticsAAVAnc80-antiVEGF via Akouos Delivery Device
ViiV Healthcarelapatinib
Prevail TherapeuticsLong Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant

Clinical Trials (9)

Total enrollment: 369 patients across 9 trials

NCT02934256Betta PharmaceuticalsIcotinib

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Start: Jul 2016Est. completion: Jul 201810 patients
Phase 2Completed
NCT02104323BiocorpEndostatin

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Start: Jan 2014Est. completion: Apr 201620 patients
Phase 2Completed
NCT06517888Prevail TherapeuticsAAVAnc80-antiVEGF via Akouos Delivery Device

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Start: Jan 2025Est. completion: Aug 202927 patients
Phase 1/2Recruiting
NCT00863122ViiV Healthcarelapatinib

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Start: Jun 2009Est. completion: Aug 201426 patients
Phase 1Completed
NCT07503613Prevail TherapeuticsLong Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Start: Mar 2026Est. completion: Apr 2040100 patients
N/AEnrolling By Invitation
NCT07035873Advanced BionicsCochlear Implant

Pediatric Cochlear Implant Remote Programming and Assessment

Start: Jan 2025Est. completion: Mar 202715 patients
N/ARecruiting
NCT06301568Advanced BionicsCochlear Implant

Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation

Start: Jan 2024Est. completion: Dec 202455 patients
N/ACompleted
NCT05488535Advanced BionicsCochlear Implant

Non-significant Risk Study of a Cochlear Implant Headpiece

Start: Feb 2019Est. completion: Feb 2020101 patients
N/ACompleted
NCT03795675Advanced BionicsCochlear Implant

CI Following VS Removal or Labyrinthectomy

Start: Jan 2019Est. completion: Dec 202715 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 369 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.